These results suggest that drug therapies in development to prevent and treat diseases associated with APOL1 high-risk genotypes might primarily affect the renal vulnerabilities that increase risk of sepsis, rather than immediate prevention of sepsis or acute treatment of sepsis once hospitalized. Here, APOL1 is linked to Sepsis.